Relmada Therapeutics annual capital expenditures (capex)
2013
2013
2014
2015
2016
2017
2018
2019
2020
Relmada Therapeutics Capital Expenditures (CapEx) Growth & History (RLMD)
Relmada Therapeutics's capital expenditures (capex) was $182.1M for fiscal 2020.
View full Relmada Therapeutics company overviewRelmada Therapeutics annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2020 | 2020-12-31 | $182.1M | $97.2M | +114.56% |
| 2019 · Dec 31 | 2019-12-31 | $84.8M | — | — |
| 2018 | 2018-06-30 | $12,391 | −$37,299 | −75.06% |
| 2017 | 2017-06-30 | $49,690 | −$512,566 | −91.16% |
| 2016 | 2016-06-30 | $562,256 | $538,930 | +2310.43% |
| 2015 | 2015-06-30 | $23,326 | $19,653 | +535.07% |
| 2014 | 2014-06-30 | $3,673 | — | — |
| 2013 · Dec 31 | 2013-12-31 | $8,871 | — | — |
| 2013 · Aug 31 | 2013-08-31 | $1,800 | — | — |
Relmada Therapeutics quarterly capital expenditures (capex)
Q3.13
Q4.13
Q1.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q4 2018 | 2018-06-30 | $9,800 | $7,598 | +345.05% |
| Q3 2018 | 2018-03-31 | $0 | −$20,227 | — |
| Q2 2018 | 2017-12-31 | $0 | −$2,434 | — |
| Q1 2018 | 2017-09-30 | $2,591 | −$22,236 | −89.56% |
| Q4 2017 | 2017-06-30 | $2,202 | −$20,841 | −90.44% |
| Q3 2017 | 2017-03-31 | $20,227 | −$42,881 | −67.95% |
| Q2 2017 | 2016-12-31 | $2,434 | −$472,361 | −99.49% |
| Q1 2017 | 2016-09-30 | $24,827 | $23,517 | +1795.19% |
| Q4 2016 | 2016-06-30 | $23,043 | $19,173 | +495.43% |
| Q3 2016 | 2016-03-31 | $63,108 | $60,822 | +2660.63% |
| Q2 2016 | 2015-12-31 | $474,795 | $468,295 | +7204.54% |
| Q1 2016 | 2015-09-30 | $1,310 | −$9,360 | −87.72% |
| Q4 2015 | 2015-06-30 | $3,870 | — | — |
| Q3 2015 | 2015-03-31 | $2,286 | $1,687 | +281.64% |
| Q2 2015 | 2014-12-31 | $6,500 | −$1,609 | −19.84% |
| Q1 2015 | 2014-09-30 | $10,670 | $9,908 | +1300.26% |
| Q1 2014 · Mar 31 | 2014-03-31 | $599 | — | — |
| Q4 2013 | 2013-12-31 | $8,109 | — | — |
| Q3 2013 | 2013-09-30 | $762 | — | — |
Relmada Therapeutics capital expenditures (capex) trends
Between the periods ended 2013-08-31 and 2020-12-31, Relmada Therapeutics's capital expenditures (capex) increased from $1,800 to $182.1M, a change of $182.0M. The latest reported quarter, Q4 2018, shows $9,800.
About the metric
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
Calculation and source
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Relmada Therapeutics source filings ↗